← Eichor
Study identifier: NCT05976490 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

NeuroPathways Intervention for Brain Tumor Patients

Condition: Malignant Brain Tumor · Glioma · Coping Skills  ·  Sponsor: Massachusetts General Hospital

PhaseNA
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This goal of this study is to test an information and support intervention for patients with malignant (or "high-grade") brain tumors. This study was developed to help patients cope after a brain tumor diagnosis. The main question this study aims to answer is whether this intervention (which includes access to an information guide and one-on-one coaching sessions) is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in the coaching sessions, use the guide as desired, and complete a small group of short surveys at three different points in time; some participants will be asked to share feedback via exit interviews.

This description comes directly from the study's public registry record.

Talk to the study team

Deborah A Forst, MD  ·  617-724-4000  ·  dforst@partners.org

Always discuss trial participation with your own doctor first.

Locations (1)

Massachusetts General Hospital Cancer CenterBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05976490